Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3

Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3

Source: 
Fierce Biotech
snippet: 

Halozyme has dropped the progression-free survival (PFS) co-primary endpoint from its phase 3 trial of PEGPH20 in metastatic pancreatic cancer.